- Preliminary revenues eased as expected to € 9.2 m in 2023 (2022: € 11.3 m) due to reduced Carragelose order volumes caused by sufficient customer stock levels
- Cash position at € 2.6 m; financial stability secured by cost-conscious cash management and convertible note funding program
- Outlook for 2024: Market introduction of Carragelose eye drops and allergen blocker, launch of nasal spray in Mexico, market authorization with Procter & Gamble for the U.S. expected
The full press release is available as download here: